10 [7] M. Moser, W. Cushman, and J. Handler, “Resistant or diﬃcult-to-treat hypertension,” Journal of Clinical Hyperten- sion, vol. 8, no. 6, pp. 434–440, 2006. [8] J. Amar, “Patients with resistant hypertension.,” Journal of Hypertensionn, vol. 25, pp. S3–S6, 2007. [9] M. Epstein, “Resistant hypertension: prevalence and evolving concepts,” Journal of Clinical Hypertension, vol. 9, no. 1, pp. 2–6, 2007. [10] R. Pisoni, M. I. Ahmed, and D. A. Calhoun, “Character- ization and treatment of resistant hypertension,” Current Cardiology Reports, vol. 11, no. 6, pp. 407–413, 2009. [11] A. D. Woolf and B. Pﬂeger, “Burden of major musculoskeletal conditions,” Bulletin of the World Health Organization, vol. 81, no. 9, pp. 646–656, 2003. [12] L. S. Lohmander, M. G. de Verdier, J. Rollof, P. M. Nilsson, and G. Engstro¨m, “Incidence of severe knee and hip osteoarthritis in relation to diﬀerent measures of body mass: a population-based prospective cohort study,” Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 490–496, 2009. [13] M. A. Weber, “Treatment of patients with hypertension and arthritis pain: new concepts,” American Journal of Medicine, vol. 122, no. 5, pp. S16–S22, 2009. [14] G. C. Curhan, W. C. Willett, B. Rosner, and M. J. Stampfer, “Frequency of analgesic use and risk of hypertension in younger women,” Archives of Internal Medicine, vol. 162, no. 19, pp. 2204–2208, 2002. [15] J. Dedier, M. J. Stampfer, S. E. Hankinson, W. C. Willett, F. E. Speizer, and G. C. Curhan, “Nonnarcotic analgesic use and the risk of hypertension in US women,” Hypertension, vol. 40, no. 5, pp. 604–608, 2002. [16] W. Zhang, R. W. Moskowitz, G. Nuki et al., “OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consen- sus guidelines,” Osteoarthritis and Cartilage, vol. 16, no. 2, pp. 137–162, 2008. [17] W. Zhang, M. Doherty, B. F. Leeb et al., “EULAR evi- dence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Stand- ing Committee for International Clinical Studies Including Therapeutics (ESCISIT),” Annals of the Rheumatic Diseases, vol. 66, no. 3, pp. 377–388, 2007. [18] J. P. Forman, E. B. Rimm, and G. C. Curhan, “Frequency of analgesic use and risk of hypertension among men,” Archives of Internal Medicine, vol. 167, no. 4, pp. 394–399, 2007. [19] J. P. Forman, M. J. Stampfer, and G. C. Curhan, “Non- narcotic analgesic dose and risk of incident hypertension in US women,” Hypertension, vol. 46, no. 3, pp. 500–507, 2005. [20] J. H. Gurwitz, J. Avorn, R. L. Bohn, R. J. Glynn, M. Monane, and H. Mogun, “Initiation of antihypertensive treatment during nonsteroidal anti-inﬂammatory drug therapy,” Jour- nal of the American Medical Association, vol. 272, no. 10, pp. 781–786, 1994. [21] J. E. Pope, J. J. Anderson, and D. T. Felson, “A meta-analysis of the eﬀects of nonsteroidal anti-inﬂammatory drugs on blood pressure,” Archives of Internal Medicine, vol. 153, no. 4, pp. 477–484, 1993. [22] A. G. Johnson, T. V. Nguyen, and R. O. Day, “Do nonsteroidal anti-inﬂammatory drugs aﬀect blood pressure? A meta- analysis,” Annals of Internal Medicine, vol. 121, no. 4, pp. 289– 300, 1994. International Journal of Hypertension [23] E. A. Chrischilles and R. B. Wallace, “Nonsteroidal anti- inﬂammatory drugs and blood pressure in an elderly popu- lation,” Journals of Gerontology, vol. 48, no. 3, pp. M91–M96, 1993. [24] A. G. Johnson, L. A. Simons, J. Simons, Y. Friedlander, and J. McCallum, “Non-steroidal anti-inﬂammatory drugs and hypertension in the elderly: a community-based cross- sectional study,” British Journal of Clinical Pharmacology, vol. 35, no. 5, pp. 455–459, 1993. [25] K. L. Radack, C. C. Deck, and S. S. Bloomﬁeld, “Ibuprofen interferes with the eﬃcacy of antihypertensive drugs. A ran- domized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen,” Annals of Internal Medicine, vol. 107, no. 5, pp. 628–635, 1987. [26] J. P. Chalmers, M. J. West, L. M. H. Wing, A. J. Bune, and J. R. Graham, “Eﬀects of indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients,” Clinical and Experimental Hypertension A, vol. 6, no. 6, pp. 1077–1093, 1984. [27] J. J. Nawarskas, R. R. Townsend, M. D. Cirigliano, and S. A. Spinler, “Eﬀect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan,” American Journal of Hypertension, vol. 12, no. 8, pp. 784–789, 1999. [28] F. Avanzini, G. Palumbo, C. Alli et al., “Eﬀects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients,” American Journal of Hypertension, vol. 13, no. 6, supplement, pp. 611–616, 2000. [29] T. Kurth, C. H. Hennekens, T. Sturmer et al., “Analgesic use and risk of subsequent hypertension in apparently healthy men,” Archives of Internal Medicine, vol. 165, no. 16, pp. 1903–1909, 2005. [30] T. J. Aw, S. J. Haas, D. Liew, and H. Krum, “Meta-analysis of cyclooxygenase-2 inhibitors and their eﬀects on blood pressure,” Archives of Internal Medicine, vol. 165, no. 5, pp. 490–496, 2005. [31] F. Wolfe, S. Zhao, M. Reynolds, and D. Pettitt, “Blood pressure destabilization and edema among 8538 users of cele- coxib, rofecoxib, and nonselective nonsteroidal antiinﬂam- matory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care,” Journal of Rheumatology, vol. 31, no. 6, pp. 1143–1151, 2004. [32] T. M. MacDonald, J. Y. Reginster, T. W. Littlejohn et al., “Eﬀect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial,” Journal of Hypertension, vol. 26, no. 8, pp. 1695–1702, 2008. [33] C. P. Cannon, S. P. Curtis, G. A. FitzGerald et al., “Car- diovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison,” Lancet, vol. 368, no. 9549, pp. 1771–1781, 2006. [34] T. O. Morgan, A. Anderson, and D. Bertram, “Eﬀect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril,” American Journal of Hypertension, vol. 13, no. 11, pp. 1161–1167, 2000. [35] W. B. White, J. Kent, A. Taylor, K. M. Verburg, J. B. Lefkowith, and A. Whelton, “Eﬀects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors,” Hyper- tension, vol. 39, no. 4, pp. 929–934, 2002. [36] A. Whelton, W. B. White, A. E. Bello, J. A. Puma, and J. G. Fort, “Eﬀects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with